logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11304994 B1

PDFFull Text
Date of Patent:
Apr. 19, 2022

Filed:

Mar. 29, 2017

Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use

Applicant:

Ab Biosciences, Inc., Concord, MA (US);

Inventors:

Yen-Ming Hsu, Lexington, MA (US);

Jeng-Shin Lee, Lincoln, MA (US);

Hsiu-Ching Chang, Concord, MA (US);

Assignee:

AB Biosciences, Inc., Concord, MA (US);

Attorney:

Cesari & McKenna, LLP

Primary Examiner:

Nora M Rooney

Int. Cl.
CPC ...
A61K 38/47 (2006.01); C07K 14/705 (2006.01); C07K 14/78 (2006.01); C07K 16/00 (2006.01); A61P 37/06 (2006.01); A61K 9/00 (2006.01); C07K 14/47 (2006.01); C07K 14/735 (2006.01); C12N 15/62 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/47 (2013.01); A61K 9/0019 (2013.01); A61P 37/06 (2018.01); C07K 14/47 (2013.01); C07K 14/70535 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C07K 14/78 (2013.01); C07K 16/00 (2013.01); C12N 15/62 (2013.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2319/30 (2013.01); C07K 2319/70 (2013.01);
Abstract

Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purification and use of rIVIG proteins. The compositions comprise oligomeric Fc molecules which bind to Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules for the treatment of immune disorders including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves Disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins can also be used as immunomodulators in patients to reduce the immune rejection of organ transplants, stem cell transplants and bone marrow transplantation. Additionally, the present invention provides rIVIG proteins of non-human origin, for use in veterinary immune disorders, such as canine rIVIG proteins for the treatment of dogs suffering from autoimmune hemolytic anemia, immune thrombocytopenia purpura, rheumatoid arthritis, or other canine immune disorder.

Find Patent Forward Citations

Loading…